Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 1.35
SCMP's Cash to Debt is ranked higher than
70% of the 926 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. SCMP: 1.35 )
SCMP' s 10-Year Cash to Debt Range
Min: 0.86   Max: No Debt
Current: 1.35

Equity to Asset 0.50
SCMP's Equity to Asset is ranked higher than
61% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SCMP: 0.50 )
SCMP' s 10-Year Equity to Asset Range
Min: -0.21   Max: 0.82
Current: 0.5

-0.21
0.82
Interest Coverage 4.86
SCMP's Interest Coverage is ranked higher than
53% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.63 vs. SCMP: 4.86 )
SCMP' s 10-Year Interest Coverage Range
Min: 3.55   Max: 9999.99
Current: 4.86

3.55
9999.99
F-Score: 5
Z-Score: 6.32
M-Score: 4.87
WACC vs ROIC
21.46%
11.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 12.47
SCMP's Operating margin (%) is ranked higher than
81% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.10 vs. SCMP: 12.47 )
SCMP' s 10-Year Operating margin (%) Range
Min: -903.97   Max: 28.03
Current: 12.47

-903.97
28.03
Net-margin (%) 5.37
SCMP's Net-margin (%) is ranked higher than
72% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. SCMP: 5.37 )
SCMP' s 10-Year Net-margin (%) Range
Min: -906.55   Max: 41.39
Current: 5.37

-906.55
41.39
ROE (%) 8.73
SCMP's ROE (%) is ranked higher than
79% of the 895 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. SCMP: 8.73 )
SCMP' s 10-Year ROE (%) Range
Min: -130.02   Max: 154.11
Current: 8.73

-130.02
154.11
ROA (%) 3.93
SCMP's ROA (%) is ranked higher than
75% of the 930 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.82 vs. SCMP: 3.93 )
SCMP' s 10-Year ROA (%) Range
Min: -83.83   Max: 37.89
Current: 3.93

-83.83
37.89
ROC (Joel Greenblatt) (%) 32.63
SCMP's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.02 vs. SCMP: 32.63 )
SCMP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -19500.5   Max: 5678.08
Current: 32.63

-19500.5
5678.08
Revenue Growth (3Y)(%) 12.50
SCMP's Revenue Growth (3Y)(%) is ranked higher than
83% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. SCMP: 12.50 )
SCMP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -21.1   Max: 127
Current: 12.5

-21.1
127
» SCMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

SCMP Guru Trades in Q4 2013

Jim Simons 36,000 sh (-71.83%)
» More
Q1 2014

SCMP Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q3 2014

SCMP Guru Trades in Q3 2014

Paul Tudor Jones 12,761 sh (New)
» More
Q4 2014

SCMP Guru Trades in Q4 2014

Jim Simons 58,800 sh (New)
Paul Tudor Jones 12,561 sh (-1.57%)
» More
» Details

Insider Trades

Latest Guru Trades with SCMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 114.20
SCMP's P/E(ttm) is ranked higher than
69% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 48.60 vs. SCMP: 114.20 )
SCMP' s 10-Year P/E(ttm) Range
Min: 5.44   Max: 122.14
Current: 114.2

5.44
122.14
Forward P/E 13.66
SCMP's Forward P/E is ranked higher than
94% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 58.14 vs. SCMP: 13.66 )
N/A
PE(NRI) 104.60
SCMP's PE(NRI) is ranked higher than
69% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 48.50 vs. SCMP: 104.60 )
SCMP' s 10-Year PE(NRI) Range
Min: 5.42   Max: 123.08
Current: 104.6

5.42
123.08
P/B 9.30
SCMP's P/B is ranked higher than
55% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. SCMP: 9.30 )
SCMP' s 10-Year P/B Range
Min: 0.97   Max: 9.99
Current: 9.3

0.97
9.99
P/S 6.40
SCMP's P/S is ranked higher than
66% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. SCMP: 6.40 )
SCMP' s 10-Year P/S Range
Min: 1.2   Max: 6.98
Current: 6.4

1.2
6.98
PFCF 71.30
SCMP's PFCF is ranked higher than
83% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. SCMP: 71.30 )
SCMP' s 10-Year PFCF Range
Min: 3.68   Max: 346.4
Current: 71.3

3.68
346.4
POCF 64.76
SCMP's POCF is ranked higher than
72% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.53 vs. SCMP: 64.76 )
SCMP' s 10-Year POCF Range
Min: 3.64   Max: 158.17
Current: 64.76

3.64
158.17
EV-to-EBIT 45.04
SCMP's EV-to-EBIT is ranked higher than
72% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.09 vs. SCMP: 45.04 )
SCMP' s 10-Year EV-to-EBIT Range
Min: -1008.9   Max: 66.7
Current: 45.04

-1008.9
66.7
Current Ratio 2.83
SCMP's Current Ratio is ranked higher than
75% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.36 vs. SCMP: 2.83 )
SCMP' s 10-Year Current Ratio Range
Min: 1.27   Max: 9.21
Current: 2.83

1.27
9.21
Quick Ratio 2.82
SCMP's Quick Ratio is ranked higher than
80% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. SCMP: 2.82 )
SCMP' s 10-Year Quick Ratio Range
Min: 1.27   Max: 9.21
Current: 2.82

1.27
9.21
Days Inventory 7.10
SCMP's Days Inventory is ranked higher than
99% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.90 vs. SCMP: 7.10 )
SCMP' s 10-Year Days Inventory Range
Min: 3.08   Max: 3.08
Current: 7.1

Days Sales Outstanding 90.24
SCMP's Days Sales Outstanding is ranked higher than
72% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.97 vs. SCMP: 90.24 )
SCMP' s 10-Year Days Sales Outstanding Range
Min: 1.75   Max: 30.77
Current: 90.24

1.75
30.77

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 59.90
SCMP's Price/Net Current Asset Value is ranked higher than
78% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. SCMP: 59.90 )
SCMP' s 10-Year Price/Net Current Asset Value Range
Min: 1.7   Max: 26
Current: 59.9

1.7
26
Price/Tangible Book 9.30
SCMP's Price/Tangible Book is ranked higher than
61% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.29 vs. SCMP: 9.30 )
SCMP' s 10-Year Price/Tangible Book Range
Min: 1.16   Max: 11.29
Current: 9.3

1.16
11.29
Price/DCF (Projected) 20.20
SCMP's Price/DCF (Projected) is ranked higher than
73% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.24 vs. SCMP: 20.20 )
SCMP' s 10-Year Price/DCF (Projected) Range
Min: 0.16   Max: 62.73
Current: 20.2

0.16
62.73
Price/Median PS Value 2.10
SCMP's Price/Median PS Value is ranked higher than
59% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. SCMP: 2.10 )
SCMP' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 2.6
Current: 2.1

0.7
2.6
Price/Graham Number 7.10
SCMP's Price/Graham Number is ranked higher than
70% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.07 vs. SCMP: 7.10 )
SCMP' s 10-Year Price/Graham Number Range
Min: 0.95   Max: 5.32
Current: 7.1

0.95
5.32
Earnings Yield (Greenblatt) 2.00
SCMP's Earnings Yield (Greenblatt) is ranked higher than
72% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SCMP: 2.00 )
SCMP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.5   Max: 119.5
Current: 2

1.5
119.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:R3A.Germany,
Sucampo Pharmaceuticals, Inc. was incorporated on 05 December 1996. The Company is a biopharmaceutical company engaged in research, discovery, development and commercialization of proprietary drugs based on ion channel activators known as prostones. The Company is engaged in developing and/or commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and also considering other potential therapeutic applications of its drug technologies. It generates revenue primarily from product royalties, development milestone payments, clinical development activities and product sales. The Company seeks additional regulatory approvals and additional indications for AMITIZA (lubiprostone), RESCULA (unoprostone isopropyl) and other compounds. Its operations are conducted through subsidiaries based in Japan, the United States, Switzerland, the United Kingdom and Luxembourg. Its reportable geographic segments are Asia, the Americas and Europe. The Company has over 525 active issued patents based on its proprietary prostone technology. It holds all commercialization rights for unoprostone isopropyl except for Japan, Korea, Taiwan and the People's Republic of China.
» More Articles for SCMP

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: VeriFone Systems Inc, Northeast Utilities, Sucampo Pharmaceuticals Inc, Jan 26 2014 
Weekly CEO Sells Highlight: Sucampo Pharmaceuticals Inc, Family Dollar Stores Inc, Nike Inc, Hallibu Oct 21 2013 
comment on SCMP Mar 06 2013 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 08 2011 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 03 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 06 2009 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 07 2009 
Sucampo Pharmaceuticals Reports Financial Results for the Second Quarter of 2009 Aug 06 2009 


More From Other Websites
Pacira Pharmaceuticals Plunges on FDA's CRL for Exparel - Analyst Blog Mar 03 2015
Salix Posts Wider-than-Expected Q4 Loss as Sales Slump - Analyst Blog Mar 03 2015
Sucampo Announces Webcast of Its Presentation at the 27th Annual ROTH Conference Mar 03 2015
Sucampo Announces Webcast of Its Presentation at the 27th Annual ROTH Conference Mar 03 2015
3 Pharmaceutical Stocks Set for Massive Earnings Growth in 2015 - Stocks in the News Mar 02 2015
Pacira Misses Earnings Estimates in Q4, Revenues In Line - Analyst Blog Feb 25 2015
Novartis' Farydak Approved for Multiple Myeloma with Warning - Analyst Blog Feb 24 2015
Novo Nordisk's Oral Semaglutide Positive in Diabetes Study - Analyst Blog Feb 23 2015
SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 23 2015
Sucampo Announces Webcast of Its Presentation at the 2015 Cowen and Company Healthcare Conference Feb 22 2015
Sucampo Announces Webcast of Its Presentation at the 2015 Cowen and Company Healthcare Conference Feb 22 2015
Stocks From Leading Industries Feb 21 2015
Oncolytics Biotech Completes Enrolment for Reolysin Study - Analyst Blog Feb 19 2015
Celsus Plunges on Dismal Dermatology Drug Study Results - Analyst Blog Feb 18 2015
Ignyta's Lead Drug Gets Orphan Status for Colorectal Cancer - Analyst Blog Feb 18 2015
Sucampo Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2014 Earnings Call Feb 18 2015
Sucampo Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2014 Earnings Call Feb 18 2015
Novartis' (NVS) Cardiovascular Drug Granted Priority Review - Analyst Blog Feb 16 2015
Merck KGaA to Gain Full Marketing Rights to Erbitux in Japan - Analyst Blog Feb 16 2015
Shire Misses on Q4 Earnings, Revenues Beat; Shares Rise - Analyst Blog Feb 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK